Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
This prospective observational study focuses on VSP in TA patients treated with tocilizumab. Although tocilizumab was effective in alleviating inflammation and disease activity, approximately 47.3% of TA patients receiving tocilizumab showed VSP during the follow-up period. This finding was consistent with those of previous reports, which did not attract enough attention (Summarized in Supplementary Table S5). Furthermore, C3 was a predictive factor for VSP, with an AUC of 0.825 in 1 year.
Abstract and Introduction Abstract Objectives: In IgG4-related disease, the relationship between pathological findings and relapse has not been well established. This study aimed to identify the clinical and pathological predictors of disease relapse in IgG4-RD. Methods: Patients with newly diagnosed IgG4-RD (n = 71) were enrolled between January 2011 and April 2020; all cases were pathologically confirmed.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
